Boehringer, Ablynx team up on nanobodies

Boehringer Ingelheim must be happy with its previous partnership with Ablynx. Boehringer has signed a second agreement with the company to develop and commercialize up to 10 different Nanobody therapeutics. Ablynx expects to receive €75 million during the research term of the collaboration. Ablynx will also receive development milestone payments for each Nanobody that is developed-- up to €125 million as well as royalties.

Ablynx has been developing "nanobodies" for a number of ailments and has other pacts with drug developers such as Wyeth Pharmaceuticals, Novartis, Centocor, and Procter and Gamble Pharmaceuticals. These nanobodies are fragments of antibodies that are small enough to enable easier delivery that circumvents the need for injections common to antibodies.

- check out the release

Related Articles:
Ablynx inks $265M 'nanobody' development deal. Report
Biota inks $102M collaboration for Hep C program. Report
Ablynx inks licensing deal for nanobodies. Report
Ablynx pockets $50M in third round. Report

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.